Table 3.
Risk factors for invasive fungal infections.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| Factors | IFI (n=20) | No IFI (n= 362) | P-value Odds ratio (95% Confidence interval) |
P-value Odds ratio (95% confidence interval) |
| Age (years), median | 58.1 | 56.6 | 0.51 | |
| MELD, median (mean) | 25 (26.1) | 25 (26.4) | 0.78 | |
| Re-transplant | 5% (1/20) | 8% (28/362) | 1.0 0.63 (0.08–4.87) |
|
| Candida colonization before or at time of transplant | 5% (1/20) | 7% (25/362) | 1.0 0.71 (0.09–5.52) |
|
| Reoperationa | 25% (5/20) | 22% (81/362) | 0.78 1.16 (0.41–3.28) |
|
| Renal failure prior to transplant | 15% (3/20) | 16% (59/362) | 1.0 0.91 (0.26–3.19) |
|
| Renal replacement therapy post- transplanta | 25% (5/20) | 27% (96/362) | 1.0 0.92 (0.33–2.61) |
|
| Fulminant hepatic failure | 5% (1/20) | 2% (8/362) | 0.39 2.33 (0.28–19.60) |
|
| Living donor | 35% (7/20) | 12% (42/362) | 0.008 4.10 (1.55–10.86) |
0.04 2.96 (1.05–8.40) |
| Choledochojejunostomy | 20% (4/20) | 10% (36/362) | 0.15 2.26 (0.72–7.14) |
|
| Operation length >11 hours | 25% (5/20) | 16% (58/362) | 0.35 1.75 (0.61–5.00) |
|
| Intra-operative use of >40 units blood products | 0% (0/20) | 12% (42/362) | 0.15 0.18 (0.01–3.10) |
|
| Operation length >11 hours AND intra-operative use of >40 Units blood products | 0% (0/20) | 5% (17/362) | 1.0 0.48 (0.03–8.30) |
|
| Targeted antifungal prophylaxis | 50% (10/20) | 37% (135/362) | 0.34 1.68 (0.68–4.14) |
|
| Bile leaks within 30 days post-transplant | 30% (6/20) | 4% (16/362) | 0.0004 9.27 (3.15–27.29) |
0.001 7.13 (2.31–22.04) |
Note: Bile leak within 30 days post-transplant and living donor remained independent risk factors for IFI when the types of antifungal prophylaxis was forced in the multivariate analysis model.
a
Total numbers of patients who required reoperation or renal replacement therapy post-transplant are lower than in Table 1 because only factors antecedent to the IFI are included
MELD= Model for End-Stage Liver Disease